| Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States M Huang, Y Lou, J Pellissier, T Burke, FX Liu, R Xu, V Velcheti Pharmacoeconomics 35, 831-844, 2017 | 131 | 2017 |
| Cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumab-naive patients with advanced melanoma in the United States J Wang, B Chmielowski, J Pellissier, R Xu, K Stevinson, FX Liu Journal of managed care & specialty pharmacy 23 (2), 184-194, 2017 | 76 | 2017 |
| EuroQol (EQ-5D) health utility scores for patients with migraine R Xu, RP Insinga, W Golden, XH Hu Quality of life research 20, 601-608, 2011 | 65 | 2011 |
| Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States M Huang, Y Lou, J Pellissier, T Burke, FX Liu, R Xu, V Velcheti Journal of medical economics 20 (2), 140-150, 2017 | 57 | 2017 |
| EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs MR Stafford, A Hareendran, DS Ng-Mak, RP Insinga, R Xu, DE Stull Health and Quality of Life Outcomes 10, 1-8, 2012 | 48 | 2012 |
| Cost effectiveness of pembrolizumab for advanced melanoma treatment in Portugal LS Miguel, FV Lopes, B Pinheiro, J Wang, R Xu, J Pellissier, PA Laires Value in Health 20 (8), 1065-1073, 2017 | 32 | 2017 |
| Estimation with unbalanced panel data having covariate measurement error J Shao, Z Xiao, R Xu Journal of statistical planning and inference 141 (2), 800-808, 2011 | 27 | 2011 |
| Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy K Patterson, V Prabhu, R Xu, H Li, Y Meng, N Zarabi, Y Zhong, R Batteson, ... European Urology Oncology 2 (5), 565-571, 2019 | 25 | 2019 |
| Efficiency of GMM estimation in panel data models with measurement error Z Xiao, J Shao, R Xu, M Palta Sankhyā: The Indian Journal of Statistics, 101-118, 2007 | 25 | 2007 |
| Modeling the durability of ZOSTAVAX® vaccine efficacy in people≥ 60 years of age X Li, JH Zhang, RF Betts, VA Morrison, R Xu, RF Itzler, CJ Acosta, ... Vaccine 33 (12), 1499-1505, 2015 | 21 | 2015 |
| Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States R Aguiar-Ibáñez, C Hardern, F van Hees, D Lee, A Patel, N Chhabra, ... Journal of Medical Economics 25 (1), 469-480, 2022 | 16 | 2022 |
| Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in Sweden T Srivastava, VS Prabhu, H Li, R Xu, N Zarabi, Y Zhong, JM Pellissier, ... European Urology Oncology 3 (5), 663-670, 2020 | 13 | 2020 |
| Cost-effectiveness of pembrolizumab for unresectable metastatic melanoma after progression with ipilimumab in England E Marriott, C Praet, R Aguiar-Ibanez, J Pellissier, R Xu, J Wang Value in Health 18 (7), A453, 2015 | 12 | 2015 |
| Bezlotoxumab is associated with a reduction in cumulative inpatient-days: analysis of the hospitalization data from the MODIFY I and II clinical trials A Basu, VS Prabhu, MB Dorr, Y Golan, ER Dubberke, OA Cornely, ... Open forum infectious diseases 5 (11), ofy218, 2018 | 9 | 2018 |
| Cost effectiveness of pembrolizumab (keytruda®) versus ipilimumab in patients with advanced melanoma in the United States J Wang, J Pellissier, R Xu, FX Liu, K Stevinson, B Chmielowski Value in Health 19 (3), A154, 2016 | 9 | 2016 |
| Cost-effectiveness analysis of herpes zoster vaccine in adults above 50 in Singapore JY Pan, TY Hsu, KD Johnson, R Xu, CJ Acosta, K Kawai Dermatologica sinica 35 (4), 177-181, 2017 | 6 | 2017 |
| Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan. L Wang, AG Bensimon, M Sundaram, R Xu, Y Lai, Y Liu, S Mt-Isa, D Yang, ... Journal of Clinical Oncology 41 (6_suppl), 733-733, 2023 | 4 | 2023 |
| Budget-impact analysis of alternative herpes zoster vaccine strategies: a US HMO Perspective J Graham, J Mauskopf, K Kawai, KD Johnson, R Xu, CJ Acosta Journal of Managed Care & Specialty Pharmacy 22 (7), 872-888, 2016 | 4 | 2016 |
| Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of resected stage IIB or IIC melanoma in the United States S Zhang, AG Bensimon, R Xu, R Jiang, A Greatsinger, A Zhang, ... Advances in Therapy 40 (7), 3038-3055, 2023 | 3 | 2023 |
| Cost-Effectiveness of Pembrolizumab (Keytruda®) Versus Ipilimumab in Patients with Advanced Melanoma in Canada J Wang, I Chabot, W El-Hadi, R Xu, J Pellissier, I Iliopoulos Value in Health 19 (3), A153-A154, 2016 | 3 | 2016 |
